PITTSBURGH, June 3 /PRNewswire/ — A study
demonstrating the cost savings realized through the use of the
ChemoFx® Drug Response Marker for assisting selection of
treatment in recurrent ovarian cancer was published recently in the
American Journal of Obstetrics and Gynecology (AJOG).
This economic analysis of recurrent ovarian cancer patients
studied the direct costs of chemotherapy for three groups; empiric,
assay-assisted, and assay-adherent. This study demonstrated that
ChemoFx®-assisted chemotherapy may result in substantially
reduced costs compared with empiric therapy.
The publication, titled, “Impact of a Chemoresponse Assay on
Treatment Costs for Recurrent Ovarian Cancer,” evaluated the net
cost savings associated with the use of the ChemoFx® drug
response marker to aid therapeutic decisions in the setting of
recurrent ovarian cancer, and reveals a possible cost savings of
$15,600 to $24,800.
“In this tough economic time it is exciting to see cost savings
resulting from the personalized information provided by
ChemoFx® for cancer patients, physicians and the health care
system,” said Sean McDonald, CEO of
Precision Therapeutics.
About Precision Therapeutics
Precision Therapeutics, a life sciences company and leader in
the development of innovative technology, delivers personalized
diagnostics to physicians with the goal of supporting and
optimizing difficult treatment decisions for patients with cancer.
Precision’s ChemoFx®, a proprietary drug response marker,
measures an individual patients’ tumor response to a range of
therapeutic alternatives under consideration by a physicia
‘/>”/>
